Business
Revolutionizing Pharma Distribution: MEDIMNY Fosters Nationwide Integration with Innovative E-commerce Platform

Revolutionizing Pharma Distribution: MEDIMNY Fosters Nationwide Integration with Innovative E-commerce Platform

Oct 12, 2023

VMPL
New Delhi [India], October 12: At the convergence of pharma and e-commerce, a new player has emerged as the leader. MEDIMNY is reshaping the traditional boundaries of the Indian pharmaceutical supply chain. By applying advanced technology to an area, once devoid of such interventions, this early player in the pharma B2B market is offering a much-needed digital boost to the sector.
Traditionally, medicine supply has been a localized affair, with the national pharmaceutical supply chain remaining highly fragmented. MEDIMNY, however, has been working tirelessly to change this paradigm. Through their groundbreaking digital platform, distributors and chemists from across the country can connect, bringing about much-needed nationwide integration, eradicating overstocking by stockists on one hand, and providing seamless connectivity to underserved chemists. Rooted in the principles of availability, connectivity, sustainability, and profitability, MEDIMNY is proving itself to be the game-changer the industry has been waiting for.
Central to the platform is its user-centric approach. Pharmacies can view the availability of medicines in real time and compare the discounts offered by various stockists throughout the country. This comprehensive outlook brings about a level of transparency that not only fosters competition but also ensures the availability of medicines in every corner of the country. With this digital leverage, local medical shops can now compete head-to-head with B2C e-pharmacies, offering consumers better discounts while maintaining profitability.
Nisha Keshari, a senior from the BFSI industry with over 15 years of experience, founded MEDIMNY in 2019. Drawing from her exposure to Asian markets, Keshari identified the vast potential of digital e-commerce within India's rapidly evolving business landscape. Following a custom-built platform tailored to the unique needs of the B2B pharmaceutical segment, the company has expanded its services to pharmacies across India.
Despite being a relatively new platform, MEDIMNY has made significant progress. With over 22,000 users and more than 22,000 product listings, its user base demonstrates its flexibility and scalability.
It is one of the renowned online aggregators for medicine wholesale supporting multiple sellers and twenty thousand-plus retailers.
At its core, the platform addresses two critical industry challenges. For stockists, it's a unique avenue to display their inventories, enabling 24/7 liquidation of surplus stocks and reducing operational costs. And for pharmacies, it presents the opportunity to find better deals and a wider variety of medicines than typically available in their local supply chains. This symbiotic relationship facilitates better business prospects for both stockists and retailers, ultimately resulting in more affordable medication for end customers.
However, navigating the path of innovation is never without its hurdles. In fact, MEDIMNY, with its unique proposition of highly competitive rates, often had to tackle suspicions from pharmacists concerning the genuineness of products. However, once customers experienced the efficiency and reliability of the platform firsthand, these doubts were quickly dispelled.
During the recent pandemic, MEDIMNY faced tough expectations from customers seeking Covid-related products. And by persuading sellers to list these high-demand items, the platform demonstrated its adaptability during crises, further reinforcing its commitment to meet the needs of its customers. As the government prioritizes digitization, the pharma industry is witnessing transformative changes in medicine supply. This shift presents an enormous opportunity for MEDIMNY to further streamline the pharma supply chain.
As Keshari asserts, "Over time, we believe that all existing pharma distribution footprints could converge to an integrated supply chain operating model, and MEDIMNY is poised to be that model. We look forward to expanding our footprint and delivering better pricing through economies of scale."
Undoubtedly, MEDIMNY is setting new standards in the pharma industry, creating an impact, and transforming operations, one transaction at a time. If you'd like to learn more, check out their website today.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)